Karen Aiach
ceo
LYSOGENE
CHR HANSEN
France
Biography
Karen Aiach, MBA, is founding president and CEO of LYSOGENE, a clinical stage biotechnology company specialized in intracerebral gene delivery for the treatment of neurological diseases. In less than five years, Karen brought LYSOGENE’s first product SAF-301 into the clinic. SAF-301 is a gene therapy product aiming at treating a fatal lysosomal storage disease known as Mucopolysaccharidosis type 3 or Sanfilippo Syndrome.
Research Interest
Karen Aiach, MBA, is founding president and CEO of LYSOGENE, a clinical stage biotechnology company specialized in intracerebral gene delivery for the treatment of neurological diseases. In less than five years, Karen brought LYSOGENE’s first product SAF-301 into the clinic. SAF-301 is a gene therapy product aiming at treating a fatal lysosomal storage disease known as Mucopolysaccharidosis type 3 or Sanfilippo Syndrome.
